پپتون با منشا سویا یعنی 5 و6 و پپتون 1 با منشا کازئین جهت بهینه نمودن شرایط تولید پروتئین نوترکیب انتخاب شدند.
منابع
1.Andreoli T. GRWE. Andreoli and carpenter’s ceil essential of Medicine. Elsevier 2010;8th
2.Deitcher S.R and Jaff M.R., Pharmacologic and clinical characteristics of thrombolytic agents.Rev Cardiovase Med,2002.3 Suppl 2 S25-33.
3.Mark H.,Beers R.S.P.,Thomas V.Jones.,Justin L.Kaplan,Michael Berkwits,,Merck Manual of Medicine.18 th ed.2006:MERCK RESEARCH LABORATORIES,Devision of MERCK & CO.,INC.
4.Parker J.A.,et al.,Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning .Radiology,1988.166(2),441-5.
5- Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971 Oct;138(1):277-80.
6-Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 2004 Mar;27(3):155-60.
7-Carrell R, Boswell DR. Serpins: the superfamily of plasma serine proteinase inhibitors. In Proteinase Inhibitors. In: Barrelland A., Salvesen G., editors.North Holland, Amsterdam: Elsevier; 1986. p. 403-20.
8-Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984 Oct;74(4):1465-72.
9-Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983;52:655-709.
10-Higgins DL, Vehar GA. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 1987 Dec 1;26(24):7786-91.
11-Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988 Apr;262(1):199-210.
12-Holly J.L. Cardiometabolic Risk Syndrome Part V: Fibrinolytic Dysfunction Your Life Your Health. 2007.
13-Wagner OF, de VC, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest 1989 Aug;84(2):647-55.
14-Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988 Dec;12(6 Suppl A):3A-13A.
15-Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest 2001 Jan;119(1 Suppl):253S-77S.
16-Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003 Nov;89(11):1358-62.
17-Cramer P., Martinet J. Thrombolytic agents destroy blood clots. 2004.
18-MALAYSIAN BIOTECHNOLOGY COUNTRY REPORT 2009 / 2010 www.biotechcorp.com.my/Documents/…/country%20report%20double.pdf. 2010.
19-Grunewald M; Muller M; Ellbruck D; Osterhues H; Kochs M; Mohren M; Schirmer G; Ziesche S; Guloglu A; Bock R; Seifried E, Double-versus single-bolus thrombolysis with reteplase for acute myocardial infarction: a pharmacokinetic and pharmacodynamic study, FIBRINOLYSIS & PROTEOLYSIS. 1997; 11 (3): 137-145.
20-Davami F, Sardari S, Majidzadeh-A K, Hemayatkar M, Barkhordari F, Enayati S, Adeli A, Mahboudi F, A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments, BMB Rep. 2011 Jan; 44(1):34-9.
21-Wurm FM, The Industry’s Workhorses – Mammalian Expression Systems, Modern Biopharmaceuticals. 2005; 723-59.
22-.Rijken DC.Wijngaards G.Zaa-de JongM. Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue.Biochim Biophys Acta.1979,580,140-53.
23.Dawson,S and A.Henney,The status pf PAI-I as a risk factor for arterial and thrombotic disease: a review.Atherosclerosis,1992,95,105-17.
24.Hoffman,C.,Hematology : Basic Principles and Practice .5th ed,:Elsevier.Chapter A.
25-Pavlou, A. K. and Reichert, J. M. 2004 Recombinant protein therapeutics–success rates, market trends and values to 2010. Nat. Biotechnol 22, 1513-1519.
26.Sandra J,Degen F,Rajput B The human tissue plasminogen activator gene.The journal of biological chemistry .1986,261,6972-6985.
27-Wurm, F. and Bernard, A. 1999 Large-scale transient expression in mammalian cells for recombinant protein production. Curr. Opin. Biotechnol 10, 156-159.
28.Korninger C.,Speiser W., Wojta J.,Binder BR.Sandwich Elisa for t-PA antigen employing a monoclonal antibody.Thromb Res.1986,41,527-535.
29.Meijer P.,Boon R.,Jie AFH.,Rosen S.,kluft C. Bioimmunoassay for tissue –type plasminogen (t-PA) in human plasma: evaluation of blood sampling and handling procedures and comparison with other t-PA activity methods.Fibrinolysis.1992,6(suupl3),97-99.
30.Krause J.Catabolism of tissue-type plasminogen activator (t-PA),its variants ‘mutants and hybrids.Fibrinolysis.1988,2,133-142.
31.Wing Hawksworth GM.,Bennet B.,Booth NA. Clearance of t-PA.,PAI-I.,and t-PA- PAI-I complex in an isolated perfused rat liver system. Journal of Laboratory and Clinical Medicine .1991,117,109-114.
32.Ranby M.,Bergsdorf N.,Pohl G.,and Wallen P.Isolation of two variants of native one chain tissue plasminogen activator.FEBS Letts.1982,146,289-296.
33.Griffith J.B.,Electricwala A.,Production of tissue plasminogen activators from animal cells.Adv Biochem Engin Biotech.1987,34,147-166.
34.Rouf S.A.,Moo-Young M.Chisi Y Tissue –type plasminogen activator: characteristics ‘application and production technology.Biotechnology Advances.1996,14,226-39.
35.Baruah,D.B.,et al .,Plasminogen activators: a comparison. Vascul Pharmacol. 2006.44(1),1-9.
36.Coleman.J.L.and J.L.Benach,Use of the plasminogen activation system by microorganisms.J Lab Clin Med.1999,134(6),567-76.
37.Ouriel,K.and K.Kandarpa,safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion : a comprehensive compilation of published work.J Endovasc Ther,2004,11(4),436-46.
38.Stroughton,J.,et al .,Plasminogen acceleration of urokinase thrombolysis.J Vasc Surg,1994.19(2),298-303,discussion 303-5.
39.Ouriel,K., et al., Comparison of streptokinase,urokinase,and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis.J Vasc Surg.1995,22(5),593-7.
40-Smalling RW, Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur. Heart J. 1997; 18(suppl. F):F11–F16.
41-Tanswell P, Tebbe U, Neuhaus KL et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
42-Seifried E, Tanswell P, Rijken DC et al. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Drug Res 1988; 38: 418-22.
43-Bode C, Kohler B, Smalling RW, Runge MS, Reteplase (r-PA): A novel recombinant plasminogen activator, Fibrinolysis, 1995; 9 (1): 97–99.
44-Grunewald M; Muller M; Ellbruck D; Osterhues H; Kochs M; Mohren M; Schirmer G; Ziesche S; Guloglu A; Bock R; Seifried E, Double-versus single-bolus thrombolysis with reteplase for acute myocardial infarction: a pharmacokinetic and pharmacodynamic study, FIBRINOLYSIS & PROTEOLYSIS. 1997; 11 (3): 137-145.
45-Dunn CJ, Goa KL, Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction, Am J Cardiovasc Drugs. 2001; 1(1):51-66.
46-Liya Davydov, Judy W.M. Cheng, Tenecteplase: a review, Clin Thel, 2001; 23:982-997.
47-Verstraete M, Third-generation thrombolytic drugs, Am J Med. 2000; 109(1):52-.
اختصارات
AMI Acute Myocardial Infarction
CHD Coronary Heart Disease
CHO Chinese Hamster Ovary (cells)
CVD Cardiovascular Diseases
DHFR Dihydrofolate Reductase
ELISA Enzyme Linked Immunosorbent Assay
F domain Finger Domain
GFP Green Fluorescent Protein
HEK293 Human Embryonic Kidney 293
IU International Unit
K1 Kringle 1
K2 Kringle 2
PCR Polymerase Chain Reaction
PCV Packed Cell Volume
r PAI-1 Recombinant Plasminogen Activator Inhibitor-1
S domain Serine Protease Domain
SFM Serum Free Media
SGE Stable Gene Expression
TGE Transient Gene Expression
t-PA Tissue Plasminogen Activator
VPA Valproic Acid
Optimization of recombinant protein production in TGE system
Abstract
Eukaryotic expression systems are the most prevalently used hosts in recombinant protein production, due to their appropriate post translational modifications. Nowadays, almost 60-70% of recombinant proteins are successfully produced in CHO cells Chinese hamster ovary (CHO) cells are capable of providing the correct protein glycosylation, and adapted to suspension growth at high cell density in large bioreactors.

دسته بندی : No category

دیدگاهتان را بنویسید